Navigation Links
Columbia researchers work to prevent blindness from age-related macular degeneration
Date:5/18/2011

NEW YORK Slowing down the aggregation or "clumping" of vitamin A in the eye may help prevent vision loss caused by macular degeneration, research from Columbia University Medical Center has found.

Rather than changing the way the eye processes vitamin A, a team of researchers led by Ilyas Washington, a professor in the department of ophthalmology at Columbia's Harkness Eye Institute, decided to focus on changing the structure of vitamin A itself. In turn, Dr. Washington and his lab have taken a novel step toward treating age-related macular degeneration (AMD), a top cause of untreatable blindness and Stargardt's disease, the most common cause of juvenile macular degeneration.

During the sequence of events that enables vision, vitamin A undergoes a series of chemical transformations in the eye. These processes sometimes allow vitamin A to react with another molecule of vitamin A to form clumpy deposits, or what are known as "vitamin A dimers." Macular degeneration has long been thought to be associated with the formation of these dimers in the eye.

The concentrations of these dimers are higher in the eyes of the elderly and in those with certain inherited eye diseases. Vitamin A dimers are also found together with insoluble pigment granules called lipofuscin. In eye diseases such as dry-AMD, the accumulation of vitamin A dimers and these granules is thought to happen over decades. But in genetic diseases such as Stargardt's disease, this process can happen much faster, leading to early vision loss as early as age 8.

"Researchers have tried a different approach to preventing the formation of vitamin A dimers by modifying the processing of vitamin A by the eye," Dr. Washington says. "But these modifications seem to have inhibited vision and caused side effects."

In animal model studies, Dr. Washington's lab has set about synthesizing a modified vitamin A drug incorporating the hydrogen isotope deuterium rather than protonium (the more abundant isotope of hydrogen) at select positions. Dr. Washington and his lab hypothesized that these modifications would make the bond involved in dimerization harder to break, which would slow dimerization. By feeding this new vitamin A drug to healthy mice, they were able to reduce the amount of vitamin A dimers without any observed side effects, said Dr. Washington, the Michael Jaharis Assistant Professor of Ophthalmic Sciences at Columbia.

When given to mice with the same genetic defect as humans with Stargardt's disease, which usually experience early vision loss, the modified vitamin A resulted in fewer vitamin A dimers, better overall ocular health and improved vision. Importantly, they also observed that the modified vitamin A behaved exactly as normal vitamin A does in all other aspects, making it an attractive potential therapy for preventing blindness in humans.

This work is detailed in a series of articles published recently in the Journal of Biological Chemistry, entitled "Deuterium Enrichment of Vitamin A at the C20 Position Slows the Formation of Detrimental Vitamin A Dimers in Wild-type Rodents" and "C20-D3-vitamin A Slows Lipofuscin Accumulation and Electrophysiological Retinal Degeneration in a Mouse Model of Stargardt's Disease."

Dry-AMD affects some 10 million Americans and is the leading cause of blindness in the Western world. Among them, approximately 3 million Americans are at high risk of irreversible vision loss, and 1 million of them are seriously visually impaired due to a late form of dry-AMD. There is currently no treatment for dry-AMD.

Although affecting only 1 in 10,000 individuals, Stargardt's disease is the most common form of inherited macular degeneration and is caused by mutations in a gene responsible for vitamin A processing. Altered vitamin A processing in Stargardt's leads to faster vitamin A dimer formation and subsequently lipofuscin accumulation and to the early onset of visual symptoms, leading to legal blindness in almost all cases. There is no current treatment for Stargardt's disease.

Dr. Washington's lab has been awarded a $1.25 million grant from the National Eye Institute to further investigate the link between vitamin A dimers and various retinal degenerations. The grant will help further the scientific understanding of how vitamin A dimers, lipofuscin and macular degenerations are related, and could result in new approaches to treat these diseases. Alkeus Pharmaceuticals has licensed from Columbia certain patents relating to Dr. Washington's discoveries and intends to launch clinical trials for Stargardt's disease and dry-AMD.


'/>"/>

Contact: Alex Lyda
alyda@columbia.edu
212-305-3900
Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. NY Presbyterian/Columbia research presented at Digestive Disease Week meeting
2. Columbia Business School hosts American Healthcare Landscape in 2014 Leadership Forum
3. Columbia Business Schools Frank Lichtenberg awarded by the Emerald Literati Network
4. Columbia business school’s Frank Lichtenberg awarded by the Emerald Literati Network
5. Harvard expert on inflammations role in obesity receives Columbias 2010 Naomi Berrie Award
6. Columbia Extreme Job Makeover Slated for June 26
7. Compex Sponsors Team HTC Columbia
8. New, National Amnesty International Report Finds Appalling U.S. Death Rate for Women Having Babies, Systemic Failures and Shocking Disparities in Maternal Health Care System; District of Columbia is 51st Among All States in Maternal Mortality
9. DTM Systems Corporation Ranked Number One as the Largest Reseller in British Columbia to Hewlett Packard Canada
10. Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories CRINONE(R) Progesterone Gel Product Line
11. Hebrew University researchers show octopuses make some pretty good moves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology: